Sage Therapeutics Inc. Stock
Sage Therapeutics Inc. Stock
Pros and Cons of Sage Therapeutics Inc. in the next few years
Pros
Cons
Performance of Sage Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Sage Therapeutics Inc. | - | - | - | - | - | - | - |
| Ironwood Pharmaceuticals | 0.640% | -5.455% | 95.000% | -6.587% | -25.714% | -73.099% | -68.163% |
| Novocure Ltd | 2.370% | -8.174% | -3.254% | -63.646% | -65.282% | -86.701% | -91.689% |
| Iovance Biotherapeutics Inc. | 0.210% | -10.811% | 19.228% | -77.316% | -72.705% | -70.951% | -94.691% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When delving into the financial landscape of SAGE Therapeutics (SAGE), a company operating within the Biotechnology & Medical Research sector, the analysis reveals a mixture of challenges and potential. The company's financial statements indicate significant operational losses and underlying volatility, suggesting a need for strategic reevaluation. Despite these hurdles, there are parts of the financial structure that show promise, particularly in revenue growth and the company's future plans.
Market Capitalization: With a market capitalization of approximately $620 million, SAGE maintains a presence in the competitive biotechnology sector. This positioning could attract potential investors seeking opportunities in innovative medical research.
Revenue Growth: The quarterly revenue growth year-over-year stands at a healthy 1.39%. This growth can be a beacon of hope for investors, suggesting that, despite losses, SAGE is finding ways to expand its revenue base.
Comments